Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33364240

about

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Neuropathic cancer pain: What we are dealing with? How to manage it?Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.New targets for the treatment of follicular lymphoma.Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.The resistance mechanisms of proteasome inhibitor bortezomib.Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Targeted therapy in lymphoma.Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent

P2860

Q24654958-146368E9-3981-4B72-8314-68973123465F Q26772907-5CC2851B-03DA-4000-9E86-E1A0DA5CDC40 Q26998945-8B5F4DBC-5EC6-441B-842F-F52CA1345975 Q27304386-4563D991-F665-403D-AE3E-33149FAC722A Q28075606-25917B98-72D3-468A-9A66-2D94F3A3C4E4 Q30248842-2AD587BE-5C97-47D7-A85B-CD207CDFB585 Q33303627-EB4B4AC6-3550-4E8E-A716-2E0CE45B0FF0 Q33375800-AA1CF887-0D11-4725-9665-17562B390931 Q33378902-A7D54FD1-9D45-4897-BF75-152647E46FD3 Q33379044-AF71055C-1AA9-4403-8DC9-BDD318E2EC5B Q33385670-C344020A-2A79-497A-B81D-E6BBB570A68F Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C Q33391725-A5DA0BEB-12AB-4BD4-9964-F49C2149AD01 Q33393623-FE0D05C3-C270-49E6-BFF3-168A12FE1F81 Q33394153-F89CD013-C609-43D0-8382-5E61E1336AE8 Q33394873-154E4A3B-4B1C-4145-BB98-B55A8D55ECB9 Q33396522-CA76E023-D90C-46D5-BA17-9DA3BBB04D26 Q33398415-E95BA4A9-4B2D-4A86-89F9-A247D168428E Q33404090-F5A22F6F-604F-4B42-8411-43452725D0AA Q33409608-B05CF3A6-782B-449A-BEAC-A8FD8FD45EB0 Q33414307-98C6E135-40D0-4A37-ABCC-52ECAEF446AB Q33414603-9385E9DD-523A-4BCB-B7D3-483F99AE4E84 Q33416533-AF15DFE6-EFBA-4E67-AEF6-F2D3976A3465 Q33418257-756A32D0-81F7-431E-87F4-D20F4FDD2D33 Q33443555-1AF7678A-AA06-4604-8553-D73E39362050 Q33586239-B6D51FB3-7E96-4911-AB46-6DC7171E2B13 Q33587396-85BAAA29-CC1A-478D-BC37-C025A8DC97FE Q33669018-C6E52D56-8362-43D4-844E-7A89CCBFBD93 Q33713106-51218B4F-CE80-4C01-BBA7-AB0B8F0FE126 Q33890300-EFE27BFE-4BAB-4E71-98F7-91168E4A1774 Q33989217-2E6F7031-1AA3-446C-ADE0-89273E27AE04 Q34129360-F6F4889B-55AE-4365-AED1-B43B9634DA6D Q34256126-E23E7008-3F37-4061-9305-CF685BBD73C0 Q34372977-CC4EAA63-FEEC-4FB0-AA78-228B4819072E Q34413686-65878658-9DA9-489E-A032-508F54EF5670 Q34541718-BB2553C7-5ADA-4342-A748-760580165CCB Q34542087-273387F5-00DC-4E29-972C-4F7CB4768DFC Q34568868-6DCC397A-216E-4FF0-B5A5-527E38AEC45A Q34608608-2043B6E4-286C-4622-A5A3-797AEBE3C1A9 Q34610605-43F52A5A-6794-46EC-8A9D-8C58E2A8C9F9

P2860

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33364240

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@ast

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@en

type

label

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@ast

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@en

prefLabel

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@ast

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@en

P1433

Q33364240-DC11B1A6-E67A-46FE-B11D-2D806A0EE89F

P1476

Q33364240-0B78A8FF-8708-4074-9E5F-0329AA7C091F

P2093

Q33364240-0E855A6F-3969-4706-98D5-E4F75FE83F90

Q33364240-0EDE11CD-603D-4665-9F0B-E1808ADCE8ED

Q33364240-24D5D28E-7951-4519-AB6D-1D2A83C8ECA3

Q33364240-31921A74-1F9E-43AF-A345-7031BF88E5AE

Q33364240-484202CF-8530-4A84-9E81-036DB1A994E9

Q33364240-4C65B77D-F2C9-4F92-8784-EB3A09F188B9

Q33364240-4ECD415F-BB18-4280-9009-3D6D72CDEDD4

Q33364240-69DC7C13-684C-438C-BBA3-6E203FAC5336

Q33364240-901D55B1-8265-4A6F-9228-D76E71C0871D

Q33364240-92DE7144-44D2-4844-8DD5-269B05F90E4A

P304

Q33364240-42039CAF-0E16-44F3-984C-F7EE8E16CC40

P31

Q33364240-36F61866-E1F9-4FE2-AB8F-ACEC53735C86

P356

Q33364240-A6B6C8BA-4EB6-4E6D-8AD2-BE21BA495EF1

P407

Q33364240-230BD95A-B9C4-4ADA-8A23-74D54CA2AF10

P433

Q33364240-ADB0E5D1-F50A-4668-9FE4-EEECC3D647D2

P478

Q33364240-A6DC34DF-C12F-4C3A-BDC4-B9B014D792C5

P50

Q33364240-05889CC3-1591-4E54-9CBD-FCE18EDEBC04

Q33364240-78C0C4B3-F614-4608-9B8B-41325525F4DB

P577

Q33364240-DE537291-A4D9-484B-831E-11760B51B7F9

P698

Q33364240-13CA94D1-9417-415E-8D77-B255AC47E634

P356

JCO.2005.03.108

P1433

Journal of Clinical Oncology

P1476

Phase II study of proteasome i ...... B-cell non-Hodgkin's lymphoma.

@en

P2093

Alma M Rodriguez

http://www.w3.org/2001/XMLSchema#string

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Andre Goy

http://www.w3.org/2001/XMLSchema#string

Andreas H Sarris

http://www.w3.org/2001/XMLSchema#string

Barbara Pro

http://www.w3.org/2001/XMLSchema#string

Barry Samuels

http://www.w3.org/2001/XMLSchema#string

David Schenkein

http://www.w3.org/2001/XMLSchema#string

Elizabeth Trehu

http://www.w3.org/2001/XMLSchema#string

Felipe Samaniego

http://www.w3.org/2001/XMLSchema#string

Frederic Gilles

http://www.w3.org/2001/XMLSchema#string

P304

667-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.108

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Cabanillas

P577

2004-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15613697

http://www.w3.org/2001/XMLSchema#string